Table 2.
Twenty-five microarray datasets including acute inflammations, metabolic diseases, autoimmune diseases, and organ failure diseases in the National Institutes of Health (NIH)–National Center for Biotechnology Information (NCBI)–Gene Expression Omnibus (GEO) dataset database (https://www.ncbi.nlm.nih.gov/gds/) were collected to analyze the expression changes of organelle crosstalk regulators (OCRGs).
| GEO ID | Disease/phenotype | Tissue | Comparison | Upregulated | Downregulated | PMID |
|---|---|---|---|---|---|---|
| Acute inflammation | ||||||
| GSE32707 | Lung injury | Whole blood | Sepsis day 0 vs. without sepsis | 4 | 8 | 22461369 |
| Lung injury | Whole blood | Sepsis day 7 vs. without sepsis | 6 | 2 | 22461369 | |
| Lung injury | Whole blood | Sepsis ARDS day 0 vs. without sepsis ARDS | 2 | 10 | 22461369 | |
| Lung injury | Whole blood | Sepsis ARDS day 7 vs. without Sepsis ARDS | 7 | 5 | 22461369 | |
| GSE13904 | Septic shock | Whole blood | Sepsis day 1 vs. normal | 13 | 6 | 19325468 |
| Septic shock | Whole blood | Sepsis day 3 vs. normal | 3 | 1 | 19325468 | |
| Septic shock | Whole blood | Sepsis shock day 1 vs. normal | 9 | 9 | 19325468 | |
| Septic shock | Whole blood | Sepsis shock day 3 vs. normal | 12 | 13 | 19325468 | |
| GSE5580 | Severe trauma | Monocytes | Severe trauma vs. health | 4 | 20 | 17032758 |
| Severe trauma | Leukocytes | Severe trauma vs. health | 3 | 21 | 17032758 | |
| Severe trauma | T cells | Severe trauma vs. health | 8 | 23 | 17032758 | |
| Metabolic disease | ||||||
| GSE2508 | Obese | Adipocytes | Non-diabetic obese vs. non-diabetic lean | 1 | 2 | 16059715 |
| GSE48964 | Obese | Adipose stem cells | Morbidly obese vs. nonobese | 0 | 1 | 24040759 |
| GSE55200 | MHO | Subcutaneous adipose | MHO vs. LH | 0 | 1 | 24933025 |
| MUO | Subcutaneous adipose | MUO vs. LH | 1 | 1 | 24933025 | |
| GSE94752 | Obese IR | Adipocytes | Obese IR vs. lean | 2 | 0 | 28570579 |
| Obese IS | Adipocytes | Obese IS vs. lean | 0 | 0 | 28570579 | |
| GSE23343 | T2D | Liver | T2D vs. normal glucose tolerance | 7 | 7 | 21035759 |
| GSE29221 | T2D | Skeletal muscle | T2D vs. non-diabetes | 10 | 22 | 23308243 |
| GSE29226 | T2D | Subcutaneous adipose | T2D vs. non-diabetes | 6 | 6 | 23308243 |
| GSE29231 | T2D | Visceral adipose | T2D vs. non-diabetes | 17 | 5 | 23308243 |
| GSE28829 | Atherosclerosis | Carotid artery | Advanced plaque vs. early plaque | 3 | 0 | 22388324 |
| GSE41571 | Atherosclerosis | Macrophages from plaques | Ruptured plaques vs. stable plaque | 14 | 11 | 23122912 |
| GSE6054 | FHC and atherosclerosis | Monocytes | FHC homozygote vs. control | 5 | 9 | 19040724 |
| GSE6088 | FHC and atherosclerosis | T cell | FHC homozygote vs. control | 4 | 7 | 19040724 |
| GSE1010 | FCH | Lymphoblastic cells | FCH vs. normal | 1 | 2 | 15388524 |
| Autoimmune disease | ||||||
| GSE10500 | RA | Macrophages* | RA vs. normal | 18 | 31 | 18345002 |
| GSE97779 | RA | Macrophages* | RA vs. normal | 25 | 40 | 28813657 |
| GSE109248 | ACLE | Skin | ACL vs. normal | 15 | 9 | 29889098 |
| CCLE | Skin | CCL vs. normal | 15 | 5 | 29889098 | |
| Psoriasis | Skin | Psoriasis vs. normal | 39 | 20 | 29889098 | |
| SCLE | Skin | SCL vs. normal | 22 | 24 | 29889098 | |
| GSE38713 | UC | Sigmoid colon or rectum | UC active involved vs. normal | 13 | 13 | 23135761 |
| GSE3365 | UC | PBMC | UC vs. normal | 1 | 4 | 16436634 |
| CD | PBMC | CD vs. normal | 2 | 1 | 16436634 | |
| Organ failure | ||||||
| GSE76701 | Heart failure | Left ventricle | Failing heart vs. non-failing heart | 1 | 2 | 26756417 |
| GSE38941 | HBV-ALF | Liver | HBV-ALF vs. normal | 24 | 25 | 23185381 |
| GSE37171 | ESRF | Whole blood | Chronic renal failure vs. healthy controls | 0 | 38 | 23809614 |
| GSE15072 | CKD hemodialysis | PBMC | Hemodialysis vs. healthy controls | 16 | 63 | 19698090 |
Expression of OCRGs was examined in a total of 39 comparison datasets. There are significantly expressed OCRGs in 38 datasets (except GSE94752 obese IS vs. lean) (p < 0.05, |logFC| > 1).
Macrophages*, macrophages from synovial fluids for RA and blood-derived macrophages for control. All the studies and samples are from humans.
ARDS, acute respiratory distress syndrome; ALI, acute liver injury; ALF, acute liver failure; PBMC, peripheral blood mononuclear cell; IS, insulin sensitive; IR, insulin resistance; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; LH, lean health; T2D, type 2 diabetes; FCH, familial combined hyperlipidemia; FHC, familial hypercholesterolemia; RA, rheumatoid arthritis; ACLE, acute cutaneous lupus; CCLE, chronic cutaneous lupus; SCLE, subacute cutaneous lupus; UC, ulcerative colitis; CD, Crohn's Disease; HBV-ALF, hepatitis B virus-associated acute liver failure; ESRF, end-stage renal failure; CKD, chronic kidney disease.